Search Results - "Dilla, T."

A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis by Núñez, M, Huete, T, de la Cueva, P, Sacristán, J A, Hartz, S, Dilla, T

“…BACKGROUND AND OBJECTIVESPsoriasis is a chronic inflammatory skin disease with an estimated prevalence in Spain of 2.3% of the population. Approximately 30% of…”
Get full text

Patient-reported outcomes assessment tools for use in psoriasis in Spain: A systematic review by Lizán, L, Gabás-Rivera, C, Belinchón, I, Dilla, T, Huete, T, Díaz, S

“…OBJECTIVESTo review the literature on validated tools for measuring patient-reported outcomes (PROs) in psoriasis in Spain. To evaluate the psychometric…”
Get full text

Patient-reported outcomes assessment tools for use in psoriasis in Spain: A systematic review by Lizán, L., Gabás-Rivera, C., Belinchón, I., Dilla, T., Huete, T., Díaz, S.

“…To review the literature on validated tools for measuring patient-reported outcomes (PROs) in psoriasis in Spain. To evaluate the psychometric properties of…”
Get full text

Atomoxetine for the Treatment of Newly Diagnosed Adults with Adhd - a Cost Effectiveness Analysis in Spain by Tockhorn, A, Televantou, F, Dilla, T

Get full text

A Cost-per-Number Needed to Treat Analysis Assessing the Efficiency of Biologic Drugs in Moderate to Severe Plaque Psoriasis by Núñez, M., Huete, T., de la Cueva, P., Sacristán, J.A., Hartz, S., Dilla, T.

“…Psoriasis is a chronic inflammatory skin disease with an estimated prevalence in Spain of 2.3% of the population. Approximately 30% of patients have…”
Get full text

Cost effectiveness of ixekizumab versus secukinumab in the treatment of moderate-to-severe plaque psoriasis in Spain by Johansson, Erin, Nuñez, Mercedes, Svedbom, Axel, Dilla, Tatiana, Hartz, Susanne

“…Currently, several biologic agents are available for the treatment of moderate-to-severe plaque psoriasis, including newer agents with similar mechanisms of…”
Get full text

Do new cancer drugs offer good value for money? the perspective of oncologists, payers, patients, and general population by Dilla, T, Lizán, L, Paz, S, Garrido, P, Avendaño, C, Cruz, J.J, Espinosa, J, Sacristan, J.A

Get full text

PMH31 Cost-Effectiveness of Long-Acting Olanzapine Versus Long-Acting Risperidone in Patients with Schizophrenia in Spain by Dilla, T, O'Donohoe, P, Möller, J, Álvarez, M, Sacristán, J, San, L, Happich, M, Tockhorn, A

Get full text

The impact of obesity in the management and evolution of diabetes mellitus by Dilla, T, Costi, M, Boye, K S, Reviriego, J, Yurgin, N, Badia, X, Lara-Suriñach, N

“…To assess both management and evolution of diabetes mellitus type 2 (DM2) in Primary Care centers in Spain and the related factors, especially obesity…”
Get more information

The MDM2 oncoprotein promotes apoptosis in p53-deficient human medullary thyroid carcinoma cells by Dilla, T, Velasco, J A, Medina, D L, González-Palacios, J F, Santisteban, P

“…The MDM2 oncoprotein has been shown to inhibit p53-mediated growth arrest and apoptosis. It also confers growth advantage to different cell lines in the…”
Get full text

Do new cancer drugs offer good value for money? The perspectives of oncologists, health care policy makers, patients, and the general population by Dilla, Tatiana, Lizan, Luís, Paz, Silvia, Garrido, Pilar, Avendaño, Cristina, Cruz-Hernández, Juan J, Espinosa, Javier, Sacristán, José A

“…In oncology, establishing the value of new cancer treatments is challenging. A clear definition of the different perspectives regarding the drivers of…”
Get full text

Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study by Longo Munoz, F., Jorge Fernandez, M., Yaya Tur, R., Diaz, S., Ortega, M., Dilla, T., Molero, A., Cervera, J.M.

Get full text

793PRamucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study by Longo Munoz, F, Jorge Fernandez, M, Yaya Tur, R, Diaz, S, Ortega, M, Dilla, T, Molero, A, Cervera, J M

“…Abstract Background Ramucirumab (RAM), as a single agent, or combined with paclitaxel, is indicated for the treatment of patients with advanced gastric cancer…”
Get full text

793P - Ramucirumab use in patients with advanced gastric cancer (AGC) or gastro-oesophageal junction (GEJ) adenocarcinoma in Spain: RAMIS observational study by Longo Munoz, F., Jorge Fernandez, M., Yaya Tur, R., Diaz, S., Ortega, M., Dilla, T., Molero, A., Cervera, J.M.

“…Ramucirumab (RAM), as a single agent, or combined with paclitaxel, is indicated for the treatment of patients with advanced gastric cancer (AGC) or…”
Get full text

PMH24 - Atomoxetine for the Treatment of Newly Diagnosed Adults with Adhd - a Cost Effectiveness Analysis in Spain by Tockhorn, A., Televantou, F., Dilla, T.

Get full text

PMU66 - COST-EFFECTIVENESS ANALYSIS OF IXEKIZUMAB VERSUS SECUKINUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND CONCOMITANT MODERATE-TO-SEVERE PSORIASIS IN SPAIN by Schweikert, B, Storck, CT, Núñez, M, Dilla, T, Hartz, S, Sapin, C

Get full text

Systematic review of the economic aspects of nonadherence to antipsychotic medication in patients with schizophrenia by Dilla, Tatiana, Ciudad, Antonio, Alvarez, María

“…There is strong evidence supporting the link between nonadherence to antipsychotic medication and relapse of schizophrenia. However, less obvious are the…”
Get full text

PMS34 - THE IMPACT OF DISEASE DURATION AND DISEASE ACTIVITY ON THE COST OF RHEUMATOID ARTHRITIS IN SPAIN: RESULTS FROM BURDEN OF RHEUMATOID ARTHRITIS ACROSS EUROPE A SOCIOECONOMIC SURVEY (BRASS) by Walid, F., Capron, J., De Leonardis, F., Dilla, T., Díaz Cerezo, S., Inciarte-Mundo, J., Burke, T.

Get full text

PMS67 - DEVELOPMENT OF A PATIENT DECISION AID (PDA) FOR PATIENTS WITH RHEUMATOID ARTHRITIS THAT REDUCES DECISIONAL CONFLICT AND IMPROVES READINESS FOR TREATMENT DECISION MAKING by Lizán, L., Pablos, J., Jover, J., Ivorra, J., Inciarte-Mundo, J., Dilla, T., Comellas, M., Sacristan, J.

Get full text

PMS112 - PATIENT AND RHEUMATOLOGIST PREFERENCES FOR THE ATTRIBUTES OF RHEUMATOID ARTHRITIS TREATMENTS IN SPAIN. A DISCRETE CHOICE EXPERIMENT by Díaz, C., Urruticoechea, A., Ivorra, J., Díaz Cerezo, S., Dilla, T., Inciarte-Mundo, J., Comellas, M., Prades, M., Lizán, L.

Get full text